Home  >  Products  >  CYP2A6 (cytochrome P450, family 2, subfamily A, polypeptide 6) Blocking Peptide (the C terminal of CYP2A6)(100ug)
CYP2A6 (cytochrome P450, family 2, subfamily A, polypeptide 6) Blocking Peptide (the C terminal of CYP2A6)(100ug)

CYP2A6 (cytochrome P450, family 2, subfamily A, polypeptide 6) Blocking Peptide (the C terminal of CYP2A6)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-CYP2A6 Antibody (ARP60126_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP60126
Size: 100ug
Weight: 56kDa
Gene: 1548
Format: Lyophilized powder
Target: CYP2A6 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to hydroxylate coumarin, and also metabolizes nicotine, aflatoxin B1, nitrosamines, and some pharmaceuticals. Individuals with certain allelic variants are said to have a poor metabolizer phenotype, meaning they do not efficiently metabolize coumarin or nicotine. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. The gene was formerly referred to as CYP2A3; however, it has been renamed CYP2A6.
Alternative names: CPA6; CYP2A; CYP2A3; P450C2A; P450PB
See Full Product Listings >